AlphAIalphai — Financial news for AI agents
marketscreener.comAUG 241 min read$MRNA

Barclays Adjusts Price Target on Moderna to $125 From $48

Barclays raised its price target for Moderna from $48 to $125. The stock is currently trading at $135.48, down 6.65% over 5 days but up 392.13% year-to-date. The adjustment reflects the bank's updated outlook on the company's prospects.

Original reporting
marketscreener.com
Published Aug 24, 2026, 10:36 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 24, 2026, 1:37 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
$MRNA
Bullish
medium confidence
Mentioned
$MRNA
Relevance
7/10
alphai data visualization · based on marketscreener.com
Decision brief

The 30-second read

$MRNABullishMed
01

Why it matters

The target increase could prompt short‑term buying pressure, but investors should monitor upcoming trial data for confirmation.

02

Market read

Analyst target lift is a fresh piece of information that may affect Moderna's stock price and biotech sector sentiment.

03

What to watch

Potential regulatory setbacks or competition could limit upside despite the target raise.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

Barclays' target revision follows internal valuation updates; no new earnings or product announcements were disclosed.

Company-level read

Ticker impact

$MRNABullishMedium confidence
Context

Barclays raised Moderna's price target to $125 from $48, indicating a bullish outlook.

Expected impact

Potential short-term price appreciation as investors adjust expectations.

Evidence & confidence

Target lift reflects improved valuation assumptions; no new corporate event, but analyst sentiment can move the stock.

Market effects

Sector

Positive signal for the biotech sector, may lift peer valuations.

Regional

Limited to US markets where Moderna trades.

Global

Moderna is a high‑profile vaccine maker; analyst upgrade can influence global biotech sentiment.

Counterpoint

What could challenge this read

Target may be overly optimistic if pipeline risks materialize.

Key entities

  • Company
    Moderna Inc.

    Biotech firm developing mRNA therapeutics and vaccines.

  • Analyst
    Barclays

    Investment bank providing equity research coverage on Moderna.

Read at source← All news

Related articles

AUG 24
$MRKMedAI 9/10

A cancer vaccine years in the making just proved itself

Merck (MRK) and Moderna (MRNA) announced positive Phase 3 trial results for their personalized cancer vaccine, Intismeran, in combination with Keytruda for melanoma. Merck's shares surged 12.5%, adding $43 billion to its market value. Analysts raised price targets, citing the vaccine's potential to offset Keytruda's patent expiration in 2028. Goldman Sachs, UBS, and Bank of America increased their targets, while RBC Capital downgraded the stock.

yahoo.com4 min
AUG 24
$MRNAHighAI 9/10

Scientists Have Dreamed About This for Decades

Moderna (MRNA) and Merck (MRK) announced positive Phase 3 trial results for their personalized cancer vaccine, Intismeran, showing significant improvement in treating melanoma. Moderna's stock surged 177% in a single day. The companies are conducting further trials across various cancers. The treatment represents a breakthrough in personalized medicine, potentially leading to FDA approval.

brownstoneresearch.com3 min
AUG 24
$MRNAHighAI 9/10

Moderna Stock Price Rockets 330% in 2026 — Is the Rally Finally Real This Time?

Moderna's stock (MRNA) surged 9% to $145.13 on August 21, capping a 70% weekly rise driven by positive late-stage trial data for a melanoma vaccine. Despite negative earnings and revenue declines, market sentiment shifted. Analysts remain cautious, with JPMorgan maintaining a sell rating. Short interest at 14% contributed to a squeeze. The stock's 52-week range is $22.28 to $176.66.

financial-news.co.uk2 min
AUG 24
$MRKMedAI 8/10

Advancement on skin cancer vaccine has future impact on Everett hospital - Everett Post

Merck and Moderna's mRNA-based skin cancer vaccine showed promising results in a phase 3 trial with 1000 patients, according to Dr. Graham Unis of Providence Everett. The vaccine targets melanoma and may offer a significant leap forward in cancer treatment, with potential applications for other cancer types. The study suggests the vaccine could prevent recurrence and spread of melanoma, with results expected soon for other cancer trials.

everettpost.com2 min
AUG 23
$MRNAHighAI 9/10

Bond Jitters Meet Biotech Fireworks

Bond market volatility pressured stocks early in the week, with the Nasdaq dropping 2.1%. Biotech stocks surged: Moderna (MRNA) rose 177% after positive cancer trial results, and Twist Bioscience (TWST) gained 23% on AI-driven protein binder success. NVIDIA's earnings and the Jackson Hole symposium are upcoming market tests.

zerohedge.com3 min
AUG 23
$MRKHighAI 9/10

StockWatch: Merck/Moderna Cancer Vaccine Gives a Shot in the Arm to Sequencing Companies, Too

Merck (MRK) and Moderna (MRNA) announced positive Phase III results for their cancer vaccine, intismeran, showing improved outcomes when combined with Keytruda. Shares of both companies surged, with Moderna gaining 130.5% over three days. Sequencing companies like Illumina (ILMN) and PacBio (PACB) also saw gains due to the personalized nature of the therapy. Analysts upgraded Moderna's stock, citing broadened sales potential, while others remained cautious about long-term expectations.

genengnews.com3 min